13 chronic haemodialysis patients, who remained hypertensive after being on long term (>12 months), thrice weekly, post HD IV rHuEPO therapy were selected for this study, with hypertension being defined as elevated blood pressure that necessitated the use of anti-hypertensive medications. These patients were switched to SC EPO thrice weekly for 6 months, whilst keeping the total weekly SC dose at two-third of the weekly IV rHuEPO dose. Their blood pressure was monitored prior to each HD session. Patient’s hypertensive therapy and red blood cell indices were also analysed regularly. The gene discussed is EPO; the disease is Hypertension.